| Literature DB >> 11295468 |
F Bugli1, R Bastidas, D R Burton, R A Williamson, M Clementi, R Burioni.
Abstract
Experimental evidence indicates Epstein Barr virus (EBV) envelope glycoprotein gp350/220 elicits a potent virus neutralizing response in the infected human host that may play an important role in restricting viral pathogenesis. In this study, we report the molecular cloning in combinatorial phage display vectors, of the IgG1 repertoire of an individual naturally infected with EBV, and describe the recovery and characterization of a monoclonal antibody recognizing gp350/220. A detailed understanding of the human antibody response in EBV infection will identify antibodies of potential use in anti-viral prophylaxis and will advance the production of more effective vaccine candidates.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11295468 DOI: 10.1016/s0198-8859(01)00216-6
Source DB: PubMed Journal: Hum Immunol ISSN: 0198-8859 Impact factor: 2.850